Lyell Immunopharma’s (LYEL) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Lyell Immunopharma (NASDAQ:LYEL) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $44.00 target price on the stock.

Several other research analysts have also issued reports on the company. B. Riley Financial started coverage on Lyell Immunopharma in a research report on Wednesday, July 22nd. They set a “buy” rating and a $44.00 target price for the company. Wall Street Zen upgraded Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, October 25th. Citigroup reissued a “market outperform” rating on shares of Lyell Immunopharma in a research note on Friday, August 14th. Royal Bank Of Canada set a $34.00 price target on Lyell Immunopharma in a research note on Friday, August 14th. Finally, HC Wainwright restated a “buy” rating on shares of Lyell Immunopharma in a research report on Friday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $40.86.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL opened at $15.00 on Tuesday. The firm has a 50 day moving average price of $10.85 and a two-hundred day moving average price of $16.69. The stock has a market cap of $367.50 million, a P/E ratio of -1.19 and a beta of -0.04. Lyell Immunopharma has a 52-week low of $7.20 and a 52-week high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.86) EPS for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.20. Lyell Immunopharma had a negative net margin of 1,701,066.75% and a negative return on equity of 101.30%. The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Analysts predict that Lyell Immunopharma will post -7.16 earnings per share for the current fiscal year.

Insider Transactions at Lyell Immunopharma

In other Lyell Immunopharma news, major shareholder Venture Fund Xiii L.P. Arch acquired 2,321,262 shares of the company’s stock in a transaction dated Wednesday, November 4th. The shares were bought at an average cost of $10.77 per share, with a total value of $24,999,991.74. Following the purchase, the insider directly owned 3,747,790 shares of the company’s stock, valued at $40,363,698.30. This trade represents a 162.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Arch Venture Partners Ix, Llc acquired 2,321,262 shares of the company’s stock in a transaction dated Wednesday, November 4th. The stock was acquired at an average cost of $10.77 per share, for a total transaction of $24,999,991.74. Following the completion of the purchase, the insider directly owned 3,747,790 shares in the company, valued at $40,363,698.30. This trade represents a 162.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have sold 1,763 shares of company stock valued at $22,052. Company insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Lyell Immunopharma

Several large investors have recently added to or reduced their stakes in LYEL. Opaleye Management Inc. increased its holdings in Lyell Immunopharma by 334.9% in the second quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock worth $4,834,000 after purchasing an additional 264,928 shares in the last quarter. venBio Partners LLC acquired a new position in Lyell Immunopharma in the second quarter valued at approximately $4,744,643. Renaissance Technologies LLC boosted its holdings in shares of Lyell Immunopharma by 194.8% during the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock worth $2,335,000 after buying an additional 76,921 shares in the last quarter. Velan Capital Investment Management LP boosted its holdings in shares of Lyell Immunopharma by 2.9% during the 2nd quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock worth $1,475,000 after buying an additional 3,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in shares of Lyell Immunopharma during the 1st quarter worth approximately $959,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma News Roundup

Here are the key news stories impacting Lyell Immunopharma this week:

• Positive Sentiment: Promising ronde-cel results: In data expected at the ASH 2026 meeting, ronde-cel produced a 91% overall response rate and 77% complete response rate among 44 patients with heavily pretreated large B-cell lymphoma; results in a 37-patient second-line cohort were 95% and 76%, respectively. Severe cytokine release syndrome was not observed in either cohort. These findings may strengthen the case for the treatment and its planned regulatory path. Ronde-cel clinical data
• Positive Sentiment: Funding and major-investor support: Lyell agreed to raise about $80 million from institutional investors, including ARCH Venture Partners, to advance ronde-cel toward a planned biologics license application. ARCH-related entities also disclosed purchases totaling about $25 million at $10.77 per share, a notable signal of investor backing. Private placement announcement SEC insider transaction filing
• Positive Sentiment: Analyst endorsement and earnings beat: Needham & Company assigned LYEL a “Buy” rating. Separately, quarterly loss per share of $1.86 was narrower than the $2.06 consensus estimate, though the company reported no revenue. Needham Buy rating Quarterly results
• Negative Sentiment: Share dilution and ongoing losses: The private placement involves issuing additional common shares, which dilutes existing holders. Lyell remains a clinical-stage company with no quarterly revenue and substantial losses, so its valuation depends heavily on future clinical and regulatory progress.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.